Skip to content

Qihuang Needle therapy Combined with Flunarizine Hydrochloride in the Treatment of Vestibular Migraine: a randomized controlled trial

Qihuang Needle therapy Combined with Flunarizine Hydrochloride in the Treatment of Vestibular Migraine: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080734
Enrollment
Unknown
Registered
2024-02-05
Start date
2022-09-05
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vestibular Migraine

Interventions

Drug group:Participants in drup group took oral Flunarizine Hydrochloride 10 mg before bed every night for two weeks
Acupuncture combined drug group:added Qihuang Needle Therapy On the basis of intervention in the drug group

Sponsors

The First Affiliated Hospital of Guangdong Pharmaceutical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria of Traditional Chinese Medicine and Western Medicine for Vestibular Migraine 2.Patients are aged 20 to 75 years 3.Did not participate in other relevant trials 4.Two weeks prior to enrollment, no medication and treatment related to the dizziness 5.Voluntarily participated in the study, and signed the written informed consent.

Exclusion criteria

Exclusion criteria: (1) Combined with severe hypertension, coronary heart disease, liver and kidney insufficiency, malignant tumor, etc. (2) Allergic to treatment drugs. (3) Those who have adopted other treatment options for VM.(4)Taked drugs or used treatment measures related to vertigo before enrollment within two weeks

Design outcomes

Primary

MeasureTime frame
Dizziness Index Score;

Secondary

MeasureTime frame
Dizziness Handicap Inventory;Video head pulse test ;

Countries

China

Contacts

Public ContactAiqun Liu

The First Affiliated Hospital of Guangdong Pharmaceutical University

179624095@qq.com+86 20 6133 7324

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026